Female Reproductive System Clear Cell Adenocarcinoma — knowledge graph

Loading the knowledge graph…

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Female Reproductive System Clear Cell Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 43show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 37 trials (8 active) · roll-up of the cancer and its descendants	—	—	Female Reproductive System Clear Cell Adenocarcinoma	37	Observed	clinicaltrials	graph →
→ investigated in trials for

Female Reproductive System Clear Cell Adenocarcinoma studied in …STUDIED_INderived100 of 100show fewer
→ studied in	NCT02446600Phase 3 · active not recruiting Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02502266Phase 2/Phase 3 · active not recruiting Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03348631Phase 2 · active not recruiting Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05112601Phase 2 · recruiting Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05920798Phase 1/Phase 2 · active not recruiting Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07718854Phase 2 · recruiting Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04575935Phase 3 · recruiting Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02101775Phase 2 · active not recruiting Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00977574Phase 2 · active not recruiting Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05950464Phase 1 · recruiting Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02839707Phase 2/Phase 3 · active not recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02068794Phase 1/Phase 2 · active not recruiting MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05046080recruiting Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT05226507Phase 1 · terminated A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04739800Phase 2 · active not recruiting Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04092270Phase 1 · active not recruiting A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04719273Phase 2 · completed Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02834013Phase 2 · active not recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type	1	Observed	clinicaltrials	graph →
→ studied in	NCT00951496Phase 3 · completed Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06730347Phase 2 · recruiting A Study of Lorigerlimab in Participants With Advanced Solid Tumors · condition mapped ALIAS · 100 trials mapped (29 active)	—	—	Vaginal Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05039801Phase 1 · recruiting IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05049538recruiting Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01737619NA · active not recruiting PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02874430Phase 2 · terminated Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02122185Phase 2 · completed Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04919629Phase 2 · recruiting APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00565851Phase 3 · active not recruiting Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03422198Phase 3 · recruiting Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02364713Phase 2 · terminated MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02111941early Phase 1 · completed Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06639074Phase 2 · recruiting Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01935934Phase 2 · completed Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06393751Phase 1/Phase 2 · withdrawn Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02713386Phase 1/Phase 2 · completed Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04906382early Phase 1 · terminated Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03648489Phase 2 · completed Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05001282Phase 1/Phase 2 · terminated A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02020707Phase 1 · completed Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02501954Phase 3 · completed Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02923739Phase 2 · terminated Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03641287NA · terminated The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05498597Phase 1 · unknown AMT-151 in Patients With Selected Advanced Solid Tumours · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02059265Phase 2 · terminated Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00492778Phase 2 · unknown Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01097746Phase 2 · completed First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03924245Phase 1 · terminated Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01307631Phase 2 · completed Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00888615Phase 2 · completed Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00989651Phase 1 · completed Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00942357Phase 3 · unknown Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02853318Phase 2 · completed Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00108745Phase 3 · unknown Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02065687Phase 2/Phase 3 · unknown Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01935973Phase 1 · completed Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02315430Phase 2 · completed Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00979992Phase 2 · completed Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01504126early Phase 1 · completed Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01074411Phase 1 · completed Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01132820Phase 2 · completed Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01196429Phase 2 · completed Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00262847Phase 3 · completed Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00993616Phase 2 · completed Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01011933Phase 2 · completed Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00079430Phase 1 · completed Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00085358Phase 1 · completed Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01459380Phase 1 · completed Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03836157Phase 2 · withdrawn Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00357448Phase 1 · completed Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00807768Phase 3 · unknown Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01489371Phase 1 · completed EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00939809Phase 2 · completed A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00899093terminated YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01275664NA · terminated Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01080521completed Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01440998Phase 1 · completed Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01005329Phase 2 · completed Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01642082Phase 2 · completed Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01210222Phase 2 · completed Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00719303Phase 3 · unknown Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Fallopian Tube Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00820898Phase 2 · completed Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00888173Phase 2 · completed Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01225887Phase 2 · completed Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00466960Phase 2 · completed Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00575952Phase 1 · completed Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00004221Phase 2 · terminated Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00897442completed Collecting Tumor Samples From Patients With Gynecological Tumors · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00059787Phase 2 · completed Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00006011Phase 3 · completed Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00060359Phase 1 · completed Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00005830Phase 1 · completed Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00005840Phase 1 · completed Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Endometrial Clear Cell Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00814086Phase 1 · completed Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01492920Phase 3 · withdrawn Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01294293Phase 1 · completed TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00002913Phase 1 · completed Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)	—	—	Ovarian Clear Cell Cystadenocarcinoma	1	Observed	clinicaltrials	graph →

Female Reproductive System Clear Cell Adenocarcinoma studied in …STUDIED_INderived100 of 100show fewer

→ studied in

NCT02446600Phase 3 · active not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer · condition mapped ONTOLOGY_EXACT · 100 trials mapped (29 active)

—

Fallopian Tube Clear Cell Adenocarcinoma

Observed

Radial view

Every edge, grouped by relationship

Strongest chains